{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T11:57:36Z","timestamp":1785585456462,"version":"3.56.0"},"reference-count":21,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100010537","name":"Nebraska Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010537","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:label\/>\n                    <jats:p>\n                      Dordaviprone is a first\u2010in\u2010class small\u2010molecule imipridone. In preclinical studies, it is active against leukemia cells harboring a TP53 mutation or complex karyotype and leukemia stem cells while sparing normal bone marrow cells. This study aimed to determine the safety of dordaviprone maintenance after allogeneic hematopoietic cell transplantation (HCT) for high\u2010risk acute myeloid leukemia (AML) and myelodysplastic neoplasm (MDS). In a Phase I trial (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200920), adults with high\u2010risk AML or MDS received escalating doses of oral dordaviprone administered weekly for up to 13 four\u2010weekly cycles (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                      ID: NCT03932643). The primary objective was to determine the rate of dose\u2010limiting toxicities (DLTs) and grade \u2265\u20093 adverse events (AEs). Participants' characteristics included a median age of 68\u2009years (range: 39\u201375\u2009years) and high\u2010risk features such as adverse\u2010risk AML (50%) or very poor\u2010risk MDS (75%), TP53 mutations (36%), or measurable residual disease before HCT (41% of AML). A total of 10 patients (one unevaluable) received 250\u2013500\u2009mg weekly doses, whereas the remaining 10 patients received 625\u2009mg weekly doses. Patients received a median of 8.5\u2009cycles (range: 1\u201313) of dordaviprone. No DLTs or graft failures were noted. Grades 3\u20134 acute GVHD was noted in 5%. Grade \u2265\u20093 AEs occurred in 45% (15% related). Grade 3\u20134 cytopenias were infrequent: anemia (15%), neutropenia (10%), and thrombocytopenia (15%). At 2\u2009years, relapse\u2010free survival and overall survival were 60% (95% confidence interval [CI]: 42%\u201386%) and 70% (95% CI: 53%\u201393%), respectively. Posttransplant dordaviprone maintenance was determined to be safe with low rates of cytopenias and promising efficacy in this high\u2010risk population.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                      identifier: NCT03932643\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ajh.70428","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T09:32:34Z","timestamp":1782466354000},"page":"2288-2296","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dordaviprone Maintenance After Allogeneic\n                    <scp>HCT<\/scp>\n                    for High\u2010Risk Acute Myeloid Leukemia and Myelodysplastic Neoplasm"],"prefix":"10.1002","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2513-0533","authenticated-orcid":false,"given":"Vijaya Raj","family":"Bhatt","sequence":"first","affiliation":[{"name":"Division of Hematology\u2010Oncology, Department of Internal Medicine University of Nebraska Medical Center  Omaha Nebraska USA"},{"name":"Fred &amp; Pamela Buffett Cancer Center University of Nebraska Medical Center  Omaha Nebraska USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher S.","family":"Wichman","sequence":"additional","affiliation":[{"name":"Department of Biostatistics University of Nebraska Medical Center  Omaha Nebraska USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa","family":"Bouska","sequence":"additional","affiliation":[{"name":"Department of Pathology, Microbiology, and Immunology University of Nebraska Medical Center  Omaha Nebraska USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6261-4898","authenticated-orcid":false,"given":"Moataz","family":"Ellithi","sequence":"additional","affiliation":[{"name":"Division of Hematology\u2010Oncology, Department of Internal Medicine University of Nebraska Medical Center  Omaha Nebraska USA"},{"name":"Fred &amp; Pamela Buffett Cancer Center University of Nebraska Medical Center  Omaha Nebraska USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Haddadin","sequence":"additional","affiliation":[{"name":"Division of Hematology\u2010Oncology, Department of Internal Medicine University of Nebraska Medical Center  Omaha Nebraska USA"},{"name":"Fred &amp; Pamela Buffett Cancer Center University of Nebraska Medical Center  Omaha Nebraska USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javeed","family":"Iqbal","sequence":"additional","affiliation":[{"name":"Department of Pathology, Microbiology, and Immunology University of Nebraska Medical Center  Omaha Nebraska USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Talmadge","sequence":"additional","affiliation":[{"name":"Department of Pathology, Microbiology, and Immunology University of Nebraska Medical Center  Omaha Nebraska USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori J.","family":"Maness","sequence":"additional","affiliation":[{"name":"Division of Hematology\u2010Oncology, Department of Internal Medicine University of Nebraska Medical Center  Omaha Nebraska USA"},{"name":"Fred &amp; Pamela Buffett Cancer Center University of Nebraska Medical Center  Omaha Nebraska USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4206-7468","authenticated-orcid":false,"given":"Krishna","family":"Gundabolu","sequence":"additional","affiliation":[{"name":"Division of Hematology\u2010Oncology, Department of Internal Medicine University of Nebraska Medical Center  Omaha Nebraska USA"},{"name":"Fred &amp; Pamela Buffett Cancer Center University of Nebraska Medical Center  Omaha Nebraska USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.08.012"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01450-3"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02175"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02474"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03277"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002544"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.07.014"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.11814"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.9b00222"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aac4380"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/15384101.2017.1403689"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.17837"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.2592"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2658"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-733196"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-420489"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0599-8"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2022.08.015"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12603-016-0797-8"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12603-009-0104-z"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-11-610543"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.70428","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ajh.70428","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.70428","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T11:19:23Z","timestamp":1785583163000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.70428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1002\/ajh.70428"],"URL":"https:\/\/doi.org\/10.1002\/ajh.70428","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"assertion":[{"value":"2026-02-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}